Betta Pharmaceuticals Co.,Ltd. (300558.SZ) has announced that its wholly-owned subsidiary, Hangzhou Jingyao Biotechnology Co., Ltd. ("Jingyao Biotech"), has received approval from Australia's Human Research Ethics Committee (HREC) for a Phase I/II clinical study of BPI-572270 capsules in patients with advanced solid tumors carrying specific RAS mutations.

The company has also completed clinical trial filing with Australia's Therapeutic Goods Administration (TGA).

This marks the company's first drug to be approved for clinical trials in Australia.